On Wednesday, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating, citing the potential of its lead candidate, tibulizumab, to deliver differentiated efficacy across severe autoimmune diseases.
Analyst Matt Phipps said the investment thesis centers on tibulizumab’s dual inhibition of key inflammatory pathways driving both T-cell and B-cell activity. He believes that mechanism could produce superior outcomes in complex, heterogeneous autoimmune conditions.
Phase 2 Trials Outpace Enrollment Goals
In June, Zura Bio announced it had completed enrollment in the Phase 2 TibuSHIELD trial evaluating tibulizumab in adults with hidradenitis suppurativa (HS).
The study exceeded its enrollment target, with 247 participants enrolled. The company also remains on track to complete enrollment in the Phase 2 TibuSURE trial in adults with early diffuse cutaneous systemic sclerosis (SSc) in early July. That study has already surpassed its target enrollment of 80 participants.
Top-line data from TibuSHIELD are expected in the fourth quarter of 2026, while results from TibuSURE are anticipated in the first half of 2027.
Zura also plans to begin a Phase 2 trial in a third immune-mediated disease by the end of 2026.
Analyst Projects Multibillion-Dollar Sales Potential
Phipps said tibulizumab has the potential to outperform currently approved therapies in both HS and SSc.
He estimates peak global sales of $2.3 billion in HS, assuming a 2031 launch, with a current net present value of $8.04 per share.
The analyst also pointed to translational data supporting tibulizumab’s mechanism in SSc, noting that autoantibodies and IL-17-driven inflammation play important roles in the disease.
While SSc has seen fewer clinical studies than HS, Phipps said positive data from the IL-17 receptor antibody brodalumab and the BAFF-targeting therapy Benlysta provide proof of concept for the dual-pathway approach and support the ongoing TibuSURE study.
William Blair projects peak global SSc sales of $1.6 billion for tibulizumab, with a potential 2031 launch and a current net present value of $4.51 per share.
As of March 31, 2026, Zura Bio held $225.6 million in cash and cash equivalents, which management expects will fund operations through at least the end of 2028.
ZURA Stock Price Activity: Zura Bio shares were up 3.15% at $5.24 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments